1-8 of 8
Brandi W. Hilder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Onsay Lau, Cuc Davis, Thomas Renaud, Jaszianne Tolbert, Brandi W Hilder, Tara J Masterson, Michela Campagna, Christoph Heuck, Ajai Chari, Niels WCJ van de Donk, Raluca Verona
Journal: Blood
Blood (2023) 142 (Supplement 1): 1933.
https://doi.org/10.1182/blood-2023-187755
Published: 2023
Journal Articles

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don A. Stevens, Leo Rasche, Xiang Qin, Kelly Kato, Timothy Ming, Eva G Katz, Katharine S Gries, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Philippe Moreau, Jesús San-Miguel, Paula Rodríguez Otero, Ajai Chari
Journal: Blood
Blood (2023) 142 (Supplement 1): 6711.
https://doi.org/10.1182/blood-2023-189151
Published: 2023
Journal Articles

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Ajai Chari, Albert Oriol, Amrita Krishnan, Maria Del Carmen Martinez Chamorro, Luciano Costa, Maria Victoria Mateos, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, M. Damiette Smit, Swarna Ramanjulu, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2023-181228
Published: 2023
Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Larysa Sanchez, Carolina Schinke, Amrita Krishnan, Jésus G Berdeja, Niels WCJ van de Donk, María Victoria Mateos, Ajai Chari, Samir Parekh, Tarek H. Mouhieddine, Sundar Jagannath, Nizar J Bahlis, Cyrille Touzeau, Albert Oriol, Jesus San-Miguel, Paula Rodriguez Otero, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Kathleen Gray, Damiette Smit, Christoph Heuck, Leo Rasche
Journal: Blood
Blood (2023) 142 (Supplement 1): 2007.
https://doi.org/10.1182/blood-2023-182330
Published: 2023
Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 3377.
https://doi.org/10.1182/blood-2023-187242
Published: 2023
Journal Articles

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Raluca I. Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Ajai Chari
Journal: Blood
Blood (2021) 138 (Supplement 1): 158.
https://doi.org/10.1182/blood-2021-146868
Published: 2021
Journal Articles

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Suzette Girgis, PhD BPharm, MS, Shun Xin Wang Lin, PhD, Kodandaram Pillarisetti, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Shoba Shetty, PhD, Tara Stephenson, PhD, Brandi W. Hilder, PhD, Brett Hanna, Jennifer Smit, Homer Adams III, PhD, Yu-Nien (Tom) Sun, PhD, Jeffrey R. Infante, MD, Yusri A Elsayed, MD PhD, Amarnath Sharma, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-140565
Published: 2020
Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-133873
Published: 2020